Marshall Wace, LLP Mereo Biopharma Group PLC Transaction History
Marshall Wace, LLP
- $77.3 Billion
- Q3 2024
A detailed history of Marshall Wace, LLP transactions in Mereo Biopharma Group PLC stock. As of the latest transaction made, Marshall Wace, LLP holds 1,028,512 shares of MREO stock, worth $3.92 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,028,512
Previous 1,144,051
10.1%
Holding current value
$3.92 Million
Previous $4.12 Million
2.65%
% of portfolio
0.01%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding MREO
# of Institutions
84Shares Held
107MCall Options Held
209KPut Options Held
479K-
Rubric Capital Management LP New York, NY15.3MShares$58.3 Million1.75% of portfolio
-
Janus Henderson Group PLC London, X012.3MShares$47 Million0.03% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA9.72MShares$37 Million0.07% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD9.53MShares$36.3 Million1.33% of portfolio
-
Mangrove Partners New York, NY8.73MShares$33.3 Million4.66% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $476M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...